Pharmacodiagnostics: Technologies, Competition, and Market Models examines the reasons why the business environment of pharmaceuticals is changing in favor of pharmacodiagnostics, and describes market models that are likely to emerge as the pharmaceutical and diagnostic industries collaborate to bring personalized medicine to fruition.
Personalized medicine promises safe drugs that work. By using diagnostic tests to identify, in advance of drug treatment, patients who are likely to be good responders and/or who are unlikely to suffer an adverse drug reaction (ADR), it is possible to improve the efficacy and safety of existing and new medicines. The tests themselves are referred to as pharmacodiagnostics, and their application to enable personalized medicine is poised to have a dramatic impact on the pharmaceutical industry, the diagnostic industry, and the overall provision of healthcare.
Pharmacodiagnostics and personalized medicine promise to address the key problems faced by the pharmaceutical industry. In addition to the clinical problems caused by ADRs, there are also well-documented commercial problems for the pharmaceutical industry, which has experienced a number of recent high-profile drug withdrawals due to unacceptable safety profiles. With the number of recalls increasing, the need for a solution is becoming critical. Furthermore, with the era of blockbuster drugs in decline, pharmaceutical companies need to incorporate personalized medicine into their drug sales models to decrease drug development costs, reduce the drug development cycle, and possibly resuscitate failed drugs.
The potential to develop personalized medicine is much greater now than at any time in the history of the drug industry. The raw data are available, and there are few technical hurdles to be overcome to allow the discovery and development of pharmacodiagnostic tests. However, the success or failure of pharmacodiagnostics will depend largely on the pull from the consumer for personalized medicine, or the push from industry. Indeed, a variety of market forces?regulatory, payer, provider, and consumer?will influence the acceptance of pharmacodiagnostics. Pharmacodiagnostics: Technologies, Competition, and Market Models analyzes these factors in detail.
Ultimately, the rise of pharmacodiagnostics will necessitate collaborative relationships between pharmaceutical and diagnostic companies with shifting power balances and opportunities for economies of scale and scope. The report projects that four principal relationships?Turnaround, Make-to-Order, Use-to-Order, and Integrated?are likely to exist. Each model is presented in terms of its varying degrees of financial benefit in return for investment in the development of companion products, underpinned by high-quality relationship management.
View Cart
